CDK2 and cancer: CDK2 acts as a critical regulator in cell cycle, that is dysregulated in many cancer types, and emerging evidence suggest that targeting CDK2 represents a therapeutic strategy for CDK2‐dependent cancers.[22] There are few studies on the role of CDK2 in ATC.